{"id":"gefitinib-raltitrexed","safety":{"commonSideEffects":[{"rate":"45%","effect":"Diarrhea"},{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL939","moleculeType":"Small molecule","molecularWeight":"446.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gefitinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).","oneSentence":"Tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:29.890Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00234429","phase":"PHASE2, PHASE3","title":"A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Colorectal Cancer","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Gefitinib, raltitrexed","genericName":"Gefitinib, raltitrexed","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}